GetTopicDetailResponse(id=6d7c1114248c, topicName=塞普替尼, introduction=塞普替尼, content=NSCLC 帕博利珠單抗 塞普替尼, image=null, comments=0, allHits=987, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Thu Feb 22 20:44:17 CST 2024, time=2024-02-22, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=487252, tagList=[TagDto(tagId=487252, tagName=塞普替尼)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2191018, encodeId=9a9d2191018c9, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=1dcf288e1cd' target=_blank style='color:#2F92EE;'>#克唑替尼#</a> <a href='/topic/show?id=6d7c1114248c' target=_blank style='color:#2F92EE;'>#塞普替尼#</a>, objectTitle=CCR：塞普替尼治療RET融合陽性肺癌當心MET擴增，聯(lián)合克唑替尼可克服！, objectType=article, longId=815908, objectId=202581590814, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=202581590814, replyNumber=0, likeNumber=134, createdTime=2024-03-04, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=202581590814, moduleTitle=CCR：塞普替尼治療RET融合陽性肺癌當心MET擴增，聯(lián)合克唑替尼可克服！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=202581590814)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188757, encodeId=c9a32188e570d, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠單抗#</a> <a href='/topic/show?id=6d7c1114248c' target=_blank style='color:#2F92EE;'>#塞普替尼#</a>, objectTitle=2023 ESMO｜李茵茵教授：塞普替尼vs化療聯(lián)合帕博利珠單抗一線治療RET融合陽性NSCLC, objectType=article, longId=814265, objectId=fc6981426596, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-doctor-review-PTX6YZP.jpg, objectUrl=/article/show_article.do?id=fc6981426596, replyNumber=0, likeNumber=149, createdTime=2024-02-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fc6981426596, moduleTitle=2023 ESMO｜李茵茵教授：塞普替尼vs化療聯(lián)合帕博利珠單抗一線治療RET融合陽性NSCLC, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fc6981426596)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-02-22發(fā)表于上海
